Top Sector Life Sciences & Health (LSH) entails a broad scope of disciplines, from pharmaceuticals to medical technology and from healthcare infrastructure to vaccination. To realise its mission – vital citizens in a healthy economy - the Top Sector builds on the strengths of the Dutch LSH sector to address the biggest societal challenges in prevention, cure and care. By funding multidisciplinary public-private partnerships (PPPs) the Top Sector aims to facilitate innovation. Here we give an overview of  a number of funded R&D projects by Top Sector LSH. The page is updated continuously.

Specialist Infant Formulas for Non-IgE Cow’s Milk Allergy

Specialist Infant Formulas for Non-IgE Cow’s Milk Allergy (SInFoNIA)

In this project University Medical Center Utrecht will collaborate with primary and secondary care centers and Nutricia Research in order to obtain more insight in the underlying mechanisms, diagnostic criteria  and corresponding clinical treatment of Cow’s Milk Allergy. Specific focus will be on infants who do not present the immunoglobulin E (IgE) or show delayed clinical symptoms.

These infants are currently treated with an extensive hydrolyzed formula based on studies in populations of mainly IgE-mediated CMA. Importantly, half of the CMA patients have non-IgE mediated CMA. Ineffective treatment leads to longer discomfort, lower Quality-of-Life and persisting food problems later in life. This research will provide more insight of the underlying pathways of non-IgE-mediated CMA and how it can be diagnosed and treated best.

This project aims to include 150 infants who are suspected of non-IgE-mediated CMA. Based on a symptom-score these children will be randomized to an extensively hydrolyzed diet or an amino acid-based formula. Clinical data (symptom resolution and tolerance acquisition) and biological samples collected over time will be analyzed and correlations will be made to immunological and microbiota parameters. With these data, the partners aim to obtain more insights and new knowledge about the underlying pathways.

The project will result in a report that will be the basis for further research as well as new product development for this specific population. In addition, it will be used to improve the clinical guidelines for treating CMA to improve symptom resolution.